Abeona Therapeutics Inc./$ABEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Ticker
$ABEO
Sector
Primary listing
Employees
136
Headquarters
Website
ABEO Metrics
BasicAdvanced
$330M
6.50
$0.99
1.54
-
Price and volume
Market cap
$330M
Beta
1.54
52-week high
$7.54
52-week low
$3.93
Average daily volume
696K
Financial strength
Current ratio
6.729
Quick ratio
6.581
Long term debt to equity
10.994
Total debt to equity
14.719
Interest coverage (TTM)
-18.01%
Profitability
EBITDA (TTM)
-72.432
Gross margin (TTM)
-8,379.75%
Net profit margin (TTM)
14,310.50%
Operating margin (TTM)
-18,634.00%
Effective tax rate (TTM)
21.32%
Management effectiveness
Return on assets (TTM)
-24.50%
Return on equity (TTM)
48.34%
Valuation
Price to earnings (TTM)
6.504
Price to revenue (TTM)
800.548
Price to book
2.01
Price to tangible book (TTM)
2.01
Price to free cash flow (TTM)
-4.491
Free cash flow yield (TTM)
-22.27%
Free cash flow per share (TTM)
-1.432
Growth
Earnings per share change (TTM)
-155.41%
3-year revenue growth (CAGR)
-54.85%
10-year revenue growth (CAGR)
-8.85%
3-year earnings per share growth (CAGR)
-61.23%
10-year earnings per share growth (CAGR)
-30.92%
Bulls say / Bears say
The FDA approved ZEVASKYN (prademagene zamikeracel) on April 29, 2025 as the first and only autologous cell-based gene therapy for RDEB, enabling a planned Q3 2025 commercial launch that establishes Abeona as a commercial-stage biotech (Reuters)
Sale of a Rare Pediatric Disease priority review voucher (PRV) for $155 million has bolstered Abeona’s cash position to approximately $225 million as of June 30, 2025, securing over two years of operating runway before ZEVASKYN revenues (Nasdaq)
Abeona has secured broad insurance coverage for ZEVASKYN, including a UnitedHealthcare policy covering over 43 million lives and a National Drug Rebate Agreement with CMS for state Medicaid programs, mitigating reimbursement risk (TipRanks)
The loss from operations widened 27% year-over-year to $22.8 million in Q2 2025, underscoring an accelerating cash burn that demands rapid ZEVASKYN revenue to sustain operations (Panabee)
Abeona faces significant manufacturing challenges inherent to autologous cell therapies, including variability in biopsy viability and potential lot failures that could delay supply scale-up and commercialization (TipRanks)
RDEB is an ultra-rare disease, limiting the addressable market; analysts estimate ZEVASKYN peak sales at $427 million by 2034, and competition from Krystal Biotech’s Vyjuvek for smaller wounds may constrain uptake (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abeona Therapeutics Inc. stock?
Abeona Therapeutics Inc. (ABEO) has a market cap of $330M as of September 14, 2025.
What is the P/E ratio for Abeona Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Abeona Therapeutics Inc. (ABEO) stock is 6.5 as of September 14, 2025.
Does Abeona Therapeutics Inc. stock pay dividends?
No, Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Abeona Therapeutics Inc. dividend payment date?
Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders.
What is the beta indicator for Abeona Therapeutics Inc.?
Abeona Therapeutics Inc. (ABEO) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.